Parkinson’s Risk Linked to Cymbalta, Celexa, Similar Antidepressants: Study
A new study links a number of antidepressants, including Celexa, Cymbalta, Lexapro and Zoloft, to an increased risk of Parkinson's disease and other movement disorders.
Tag Archives: Wellbutrin
-
-
Pravastatin Recall Issued After Bottles Found To Contain Generic Wellbutrin
A recall of generic Pravachol has been announced after tablets of generic Wellbutrin were found in some mislabeled bottles.
-
Abilify Provides Only “Modest” Effects In Treating Depression: Study
The benefits of Abilify to treat people suffering from depression are modest at best and come with an increased risk of adverse events, according to the findings of a new…
-
Side Effects of Topamax, Wellbutrin May Increase Glaucoma Risk: Study
A new study links the use of Topamax and Wellbutrin to an increased risk of a particular form of glaucoma.
-
Advair Settlement Agreement Reached With 45 States for $105M
GlaxoSmithKline will pay 45 states $105 million for illegally marketing the asthma drug Advair.
-
Study Finds No Heart Risks with Chantix, Other Anti-Smoking Products
A new study challenges previous allegations that the smoking cessation drug Chantix can increase the risk of heart problems.
-
Anti-Smoking Drug Suicide Risks Questioned by New Study
Researchers found no evidence that side effects of the smoking cessation drugs Chantix, Wellbutrin or Zyban increase the risk of suicide in a new study.
-
Appeals Court Calls Off-Label Drug Marketing Free Speech
In a decision that could fundamentally change the actions of the pharmaceutical industry in the United States, a federal appeals court has ruled that the government does not have the…
-
Generic Wellbutrin XL Recalled, Not As Effective As Original: FDA
Federal health officials have issued a recall for a generic equivalent of Wellbutrin XL, marketed by Teva Pharmaceuticals as Budeprion XL 300 mg, due to a recent study that established…
-
Pharmaceutical Whistleblowers to Share Millions From GSK Settlement
As a reward for blowing the whistle on illegal drug marketing practices at GlaxoSmithKline, four former employees will split an estimated $250 million dollars.
